STOCKHOLM, Aug 30 (Reuters) - Japanese drugmaker Eisai's (4523.T) experimental blood clot preventer E5555 may have the potential to reduce heart attacks, strokes and cardiovascular deaths without increased serious bleeding risks, Japanese researchers said.
